Analysts have been eager to weigh in on the Healthcare sector with new ratings on Esperion (ESPR) and Aptose Biosciences (APTO).
Esperion (ESPR)
In a report released today, Carl Byrnes from Northland Securities maintained a Hold rating on Esperion, with a price target of $24.00. The company’s shares closed last Tuesday at $25.59, close to its 52-week low of $23.90.
According to TipRanks.com, Byrnes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.1% and a 34.2% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Oncternal Therapeutics, Aridis Pharmaceuticals, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Esperion is a Moderate Buy with an average price target of $43.86, which is a 64.8% upside from current levels. In a report released yesterday, Stifel Nicolaus also downgraded the stock to Hold with a $20.00 price target.
See today’s analyst top recommended stocks >>
Aptose Biosciences (APTO)
In a report released today, Matthew Cross from Alliance Global Partners maintained a Buy rating on Aptose Biosciences, with a price target of $12.00. The company’s shares closed last Tuesday at $5.49.
According to TipRanks.com, Cross is a 4-star analyst with an average return of 13.2% and a 40.6% success rate. Cross covers the Healthcare sector, focusing on stocks such as Syros Pharmaceuticals, Aldeyra Therapeutics, and MEI Pharma.
Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $11.14, which is a 102.2% upside from current levels. In a report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $14.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
